Global Anti-IL-23 p19 Monoclonal Antibodies Supply, Demand and Key Producers, 2026-2032
The global Anti-IL-23 p19 Monoclonal Antibodies market size is expected to reach $ 47898 million by 2032, rising at a market growth of 8.3% CAGR during the forecast period (2026-2032).
Anti-IL-23 p19 monoclonal antibodies are recombinant therapeutic biologics designed to selectively bind the p19 subunit of interleukin 23 and treat immune-mediated inflammatory diseases. The product scope mainly covers humanized or fully human IgG monoclonal antibody injections, including prefilled syringes, autoinjectors, subcutaneous formulations and intravenous induction formulations used in selected indications. Core manufacturing processes include antibody discovery and optimization, mammalian cell expression, cell culture, protein A purification, viral inactivation, ultrafiltration and concentration, aseptic filling, cold-chain release testing and biologics quality control. Key specifications include target-binding affinity, p19 selectivity, serum half-life, dosing interval, immunogenicity, formulation stability, purity, aggregate level, potency and batch-to-batch consistency. The main therapeutic function is to inhibit IL-23-mediated activation of the Th17 inflammatory pathway and reduce downstream cytokine activity, thereby improving chronic inflammatory diseases such as moderate to severe plaque psoriasis, psoriatic arthritis, Crohn?s disease and ulcerative colitis. The industry is positioned within specialty biologics and autoimmune therapeutics, with demand driven by long-term treatment, expanded indications, improved dosing convenience and substitution from older immunology therapies. In 2025, mature commercialized anti-IL-23 p19 monoclonal antibody products generally achieved gross margins of about 80% to 90%.
Anti-IL-23 p19 monoclonal antibodies represent one of the most commercially established segments within specialty immunology biologics. The market is not characterized by a large number of manufacturers, but by a small group of approved therapies that have built strong positions through clear target selectivity, durable efficacy, convenient dosing and continuous indication expansion. The upstream chain includes cell line development, culture media, single-use bioreactors, purification resins, sterile filling materials and cold-chain systems. The midstream consists of antibody discovery, clinical development, regulatory registration, large-scale biologics manufacturing and quality release. The downstream market is concentrated in dermatology, rheumatology and gastroenterology, where chronic disease management and long treatment duration support resilient demand. Competition is highly concentrated, but the basis of competition is changing. Initial adoption was largely driven by plaque psoriasis, while future growth is increasingly linked to inflammatory bowel disease, psoriatic arthritis and broader immune-mediated conditions. New product launches and indication expansion remain the main commercial catalysts, but differentiation must be supported by sustained efficacy, safety, dosing convenience and real-world outcomes. Licensing, co-development and regional commercialization agreements are expected to remain active, particularly around late-stage pipelines and next-generation antibody formats. These transactions can improve development efficiency and accelerate geographic expansion, but they also make revenue attribution and market sizing more complex. The policy environment is broadly supportive of innovative biologics, especially where therapies address chronic inflammatory diseases with high unmet needs. At the same time, payer pressure, health technology assessment, price negotiation, biosimilar risk and patent-cycle dynamics will gradually moderate long-term growth. The industry remains a growth market, but it is moving from a rapid expansion phase toward a more mature phase driven by product differentiation and lifecycle management. Products with longer half-life, fewer injections, broader indication coverage and reliable manufacturing quality are likely to gain share, while late entrants with limited clinical or pricing advantages may face increasing commercialization pressure.
This report studies the global Anti-IL-23 p19 Monoclonal Antibodies production, demand, key manufacturers, and key regions.
This report is a detailed and comprehensive analysis of the world market for Anti-IL-23 p19 Monoclonal Antibodies and provides market size (US$ million) and Year-over-Year (YoY) Growth, considering 2025 as the base year. This report explores demand trends and competition, as well as details the characteristics of Anti-IL-23 p19 Monoclonal Antibodies that contribute to its increasing demand across many markets.
Highlights and key features of the study
Global Anti-IL-23 p19 Monoclonal Antibodies total production and demand, 2021-2032, (Unit)
Global Anti-IL-23 p19 Monoclonal Antibodies total production value, 2021-2032, (USD Million)
Global Anti-IL-23 p19 Monoclonal Antibodies production by region & country, production, value, CAGR, 2021-2032, (USD Million) & (Unit), (based on production site)
Global Anti-IL-23 p19 Monoclonal Antibodies consumption by region & country, CAGR, 2021-2032 & (Unit)
U.S. VS China: Anti-IL-23 p19 Monoclonal Antibodies domestic production, consumption, key domestic manufacturers and share
Global Anti-IL-23 p19 Monoclonal Antibodies production by manufacturer, production, price, value and market share 2021-2026, (USD Million) & (Unit)
Global Anti-IL-23 p19 Monoclonal Antibodies production by Indication, production, value, CAGR, 2021-2032, (USD Million) & (Unit)
Global Anti-IL-23 p19 Monoclonal Antibodies production by Application, production, value, CAGR, 2021-2032, (USD Million) & (Unit)
This report profiles key players in the global Anti-IL-23 p19 Monoclonal Antibodies market based on the following parameters - company overview, production, value, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include AbbVie Inc., Johnson & Johnson, Eli Lilly and Company, Sun Pharmaceutical Industries Limited, Innovent Biologics, Inc., Hansoh Pharmaceutical Group Company Limited, SUN Pharmaceuticals Industries Europe B.V., Industrias Farmac?uticas Almirall, S.A., etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the World Anti-IL-23 p19 Monoclonal Antibodies market
Detailed Segmentation:
Each section contains quantitative market data including market by value (US$ Millions), volume (production, consumption) & (Unit) and average price (US$/Unit) by manufacturer, by Indication, and by Application. Data is given for the years 2021-2032 by year with 2025 as the base year, 2026 as the estimate year, and 2027-2032 as the forecast year.
Global Anti-IL-23 p19 Monoclonal Antibodies Market, By Region:
1. How big is the global Anti-IL-23 p19 Monoclonal Antibodies market?
2. What is the demand of the global Anti-IL-23 p19 Monoclonal Antibodies market?
3. What is the year over year growth of the global Anti-IL-23 p19 Monoclonal Antibodies market?
4. What is the production and production value of the global Anti-IL-23 p19 Monoclonal Antibodies market?
5. Who are the key producers in the global Anti-IL-23 p19 Monoclonal Antibodies market?
6. What are the growth factors driving the market demand?
Anti-IL-23 p19 monoclonal antibodies are recombinant therapeutic biologics designed to selectively bind the p19 subunit of interleukin 23 and treat immune-mediated inflammatory diseases. The product scope mainly covers humanized or fully human IgG monoclonal antibody injections, including prefilled syringes, autoinjectors, subcutaneous formulations and intravenous induction formulations used in selected indications. Core manufacturing processes include antibody discovery and optimization, mammalian cell expression, cell culture, protein A purification, viral inactivation, ultrafiltration and concentration, aseptic filling, cold-chain release testing and biologics quality control. Key specifications include target-binding affinity, p19 selectivity, serum half-life, dosing interval, immunogenicity, formulation stability, purity, aggregate level, potency and batch-to-batch consistency. The main therapeutic function is to inhibit IL-23-mediated activation of the Th17 inflammatory pathway and reduce downstream cytokine activity, thereby improving chronic inflammatory diseases such as moderate to severe plaque psoriasis, psoriatic arthritis, Crohn?s disease and ulcerative colitis. The industry is positioned within specialty biologics and autoimmune therapeutics, with demand driven by long-term treatment, expanded indications, improved dosing convenience and substitution from older immunology therapies. In 2025, mature commercialized anti-IL-23 p19 monoclonal antibody products generally achieved gross margins of about 80% to 90%.
Anti-IL-23 p19 monoclonal antibodies represent one of the most commercially established segments within specialty immunology biologics. The market is not characterized by a large number of manufacturers, but by a small group of approved therapies that have built strong positions through clear target selectivity, durable efficacy, convenient dosing and continuous indication expansion. The upstream chain includes cell line development, culture media, single-use bioreactors, purification resins, sterile filling materials and cold-chain systems. The midstream consists of antibody discovery, clinical development, regulatory registration, large-scale biologics manufacturing and quality release. The downstream market is concentrated in dermatology, rheumatology and gastroenterology, where chronic disease management and long treatment duration support resilient demand. Competition is highly concentrated, but the basis of competition is changing. Initial adoption was largely driven by plaque psoriasis, while future growth is increasingly linked to inflammatory bowel disease, psoriatic arthritis and broader immune-mediated conditions. New product launches and indication expansion remain the main commercial catalysts, but differentiation must be supported by sustained efficacy, safety, dosing convenience and real-world outcomes. Licensing, co-development and regional commercialization agreements are expected to remain active, particularly around late-stage pipelines and next-generation antibody formats. These transactions can improve development efficiency and accelerate geographic expansion, but they also make revenue attribution and market sizing more complex. The policy environment is broadly supportive of innovative biologics, especially where therapies address chronic inflammatory diseases with high unmet needs. At the same time, payer pressure, health technology assessment, price negotiation, biosimilar risk and patent-cycle dynamics will gradually moderate long-term growth. The industry remains a growth market, but it is moving from a rapid expansion phase toward a more mature phase driven by product differentiation and lifecycle management. Products with longer half-life, fewer injections, broader indication coverage and reliable manufacturing quality are likely to gain share, while late entrants with limited clinical or pricing advantages may face increasing commercialization pressure.
This report studies the global Anti-IL-23 p19 Monoclonal Antibodies production, demand, key manufacturers, and key regions.
This report is a detailed and comprehensive analysis of the world market for Anti-IL-23 p19 Monoclonal Antibodies and provides market size (US$ million) and Year-over-Year (YoY) Growth, considering 2025 as the base year. This report explores demand trends and competition, as well as details the characteristics of Anti-IL-23 p19 Monoclonal Antibodies that contribute to its increasing demand across many markets.
Highlights and key features of the study
Global Anti-IL-23 p19 Monoclonal Antibodies total production and demand, 2021-2032, (Unit)
Global Anti-IL-23 p19 Monoclonal Antibodies total production value, 2021-2032, (USD Million)
Global Anti-IL-23 p19 Monoclonal Antibodies production by region & country, production, value, CAGR, 2021-2032, (USD Million) & (Unit), (based on production site)
Global Anti-IL-23 p19 Monoclonal Antibodies consumption by region & country, CAGR, 2021-2032 & (Unit)
U.S. VS China: Anti-IL-23 p19 Monoclonal Antibodies domestic production, consumption, key domestic manufacturers and share
Global Anti-IL-23 p19 Monoclonal Antibodies production by manufacturer, production, price, value and market share 2021-2026, (USD Million) & (Unit)
Global Anti-IL-23 p19 Monoclonal Antibodies production by Indication, production, value, CAGR, 2021-2032, (USD Million) & (Unit)
Global Anti-IL-23 p19 Monoclonal Antibodies production by Application, production, value, CAGR, 2021-2032, (USD Million) & (Unit)
This report profiles key players in the global Anti-IL-23 p19 Monoclonal Antibodies market based on the following parameters - company overview, production, value, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include AbbVie Inc., Johnson & Johnson, Eli Lilly and Company, Sun Pharmaceutical Industries Limited, Innovent Biologics, Inc., Hansoh Pharmaceutical Group Company Limited, SUN Pharmaceuticals Industries Europe B.V., Industrias Farmac?uticas Almirall, S.A., etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the World Anti-IL-23 p19 Monoclonal Antibodies market
Detailed Segmentation:
Each section contains quantitative market data including market by value (US$ Millions), volume (production, consumption) & (Unit) and average price (US$/Unit) by manufacturer, by Indication, and by Application. Data is given for the years 2021-2032 by year with 2025 as the base year, 2026 as the estimate year, and 2027-2032 as the forecast year.
Global Anti-IL-23 p19 Monoclonal Antibodies Market, By Region:
- United States
- China
- Europe
- Japan
- South Korea
- ASEAN
- India
- Rest of World
- Plaque Psoriasis
- Psoriatic Arthritis
- Crohn's Disease
- Ulcerative Colitis
- Others
- Humanized IgG Monoclonal Antibodies
- Fully Human IgG Monoclonal Antibodies
- Fc-engineered or Long-acting Antibodies
- Others
- Subcutaneous Injection
- Intravenous Induction plus Subcutaneous Maintenance
- Intravenous Injection
- Others
- Hospitals
- Specialist Clinics
- Infusion Centers
- Specialty Pharmacies
- Retail and DTP Pharmacies
- Others
- AbbVie Inc.
- Johnson & Johnson
- Eli Lilly and Company
- Sun Pharmaceutical Industries Limited
- Innovent Biologics, Inc.
- Hansoh Pharmaceutical Group Company Limited
- SUN Pharmaceuticals Industries Europe B.V.
- Industrias Farmac?uticas Almirall, S.A.
1. How big is the global Anti-IL-23 p19 Monoclonal Antibodies market?
2. What is the demand of the global Anti-IL-23 p19 Monoclonal Antibodies market?
3. What is the year over year growth of the global Anti-IL-23 p19 Monoclonal Antibodies market?
4. What is the production and production value of the global Anti-IL-23 p19 Monoclonal Antibodies market?
5. Who are the key producers in the global Anti-IL-23 p19 Monoclonal Antibodies market?
6. What are the growth factors driving the market demand?
1 SUPPLY SUMMARY
1.1 Anti-IL-23 p19 Monoclonal Antibodies Introduction
1.2 World Anti-IL-23 p19 Monoclonal Antibodies Supply & Forecast
1.2.1 World Anti-IL-23 p19 Monoclonal Antibodies Production Value (2021 & 2025 & 2032)
1.2.2 World Anti-IL-23 p19 Monoclonal Antibodies Production (2021-2032)
1.2.3 World Anti-IL-23 p19 Monoclonal Antibodies Pricing Trends (2021-2032)
1.3 World Anti-IL-23 p19 Monoclonal Antibodies Production by Region (Based on Production Site)
1.3.1 World Anti-IL-23 p19 Monoclonal Antibodies Production Value by Region (2021-2032)
1.3.2 World Anti-IL-23 p19 Monoclonal Antibodies Production by Region (2021-2032)
1.3.3 World Anti-IL-23 p19 Monoclonal Antibodies Average Price by Region (2021-2032)
1.3.4 North America Anti-IL-23 p19 Monoclonal Antibodies Production (2021-2032)
1.3.5 Europe Anti-IL-23 p19 Monoclonal Antibodies Production (2021-2032)
1.3.6 China Anti-IL-23 p19 Monoclonal Antibodies Production (2021-2032)
1.3.7 Japan Anti-IL-23 p19 Monoclonal Antibodies Production (2021-2032)
1.4 Market Drivers, Restraints and Trends
1.4.1 Anti-IL-23 p19 Monoclonal Antibodies Market Drivers
1.4.2 Factors Affecting Demand
1.4.3 Anti-IL-23 p19 Monoclonal Antibodies Major Market Trends
2 DEMAND SUMMARY
2.1 World Anti-IL-23 p19 Monoclonal Antibodies Demand (2021-2032)
2.2 World Anti-IL-23 p19 Monoclonal Antibodies Consumption by Region
2.2.1 World Anti-IL-23 p19 Monoclonal Antibodies Consumption by Region (2021-2026)
2.2.2 World Anti-IL-23 p19 Monoclonal Antibodies Consumption Forecast by Region (2027-2032)
2.3 United States Anti-IL-23 p19 Monoclonal Antibodies Consumption (2021-2032)
2.4 China Anti-IL-23 p19 Monoclonal Antibodies Consumption (2021-2032)
2.5 Europe Anti-IL-23 p19 Monoclonal Antibodies Consumption (2021-2032)
2.6 Japan Anti-IL-23 p19 Monoclonal Antibodies Consumption (2021-2032)
2.7 South Korea Anti-IL-23 p19 Monoclonal Antibodies Consumption (2021-2032)
2.8 ASEAN Anti-IL-23 p19 Monoclonal Antibodies Consumption (2021-2032)
2.9 India Anti-IL-23 p19 Monoclonal Antibodies Consumption (2021-2032)
3 WORLD MANUFACTURERS COMPETITIVE ANALYSIS
3.1 World Anti-IL-23 p19 Monoclonal Antibodies Production Value by Manufacturer (2021-2026)
3.2 World Anti-IL-23 p19 Monoclonal Antibodies Production by Manufacturer (2021-2026)
3.3 World Anti-IL-23 p19 Monoclonal Antibodies Average Price by Manufacturer (2021-2026)
3.4 Anti-IL-23 p19 Monoclonal Antibodies Company Evaluation Quadrant
3.5 Industry Rank and Concentration Rate (CR)
3.5.1 Global Anti-IL-23 p19 Monoclonal Antibodies Industry Rank of Major Manufacturers
3.5.2 Global Concentration Ratios (CR4) for Anti-IL-23 p19 Monoclonal Antibodies in 2025
3.5.3 Global Concentration Ratios (CR8) for Anti-IL-23 p19 Monoclonal Antibodies in 2025
3.6 Anti-IL-23 p19 Monoclonal Antibodies Market: Overall Company Footprint Analysis
3.6.1 Anti-IL-23 p19 Monoclonal Antibodies Market: Region Footprint
3.6.2 Anti-IL-23 p19 Monoclonal Antibodies Market: Company Product Type Footprint
3.6.3 Anti-IL-23 p19 Monoclonal Antibodies Market: Company Product Application Footprint
3.7 Competitive Environment
3.7.1 Historical Structure of the Industry
3.7.2 Barriers of Market Entry
3.7.3 Factors of Competition
3.8 New Entrant and Capacity Expansion Plans
3.9 Mergers, Acquisition, Agreements, and Collaborations
4 UNITED STATES VS CHINA VS REST OF THE WORLD
4.1 United States VS China: Anti-IL-23 p19 Monoclonal Antibodies Production Value Comparison
4.1.1 United States VS China: Anti-IL-23 p19 Monoclonal Antibodies Production Value Comparison (2021 & 2025 & 2032)
4.1.2 United States VS China: Anti-IL-23 p19 Monoclonal Antibodies Production Value Market Share Comparison (2021 & 2025 & 2032)
4.2 United States VS China: Anti-IL-23 p19 Monoclonal Antibodies Production Comparison
4.2.1 United States VS China: Anti-IL-23 p19 Monoclonal Antibodies Production Comparison (2021 & 2025 & 2032)
4.2.2 United States VS China: Anti-IL-23 p19 Monoclonal Antibodies Production Market Share Comparison (2021 & 2025 & 2032)
4.3 United States VS China: Anti-IL-23 p19 Monoclonal Antibodies Consumption Comparison
4.3.1 United States VS China: Anti-IL-23 p19 Monoclonal Antibodies Consumption Comparison (2021 & 2025 & 2032)
4.3.2 United States VS China: Anti-IL-23 p19 Monoclonal Antibodies Consumption Market Share Comparison (2021 & 2025 & 2032)
4.4 United States Based Anti-IL-23 p19 Monoclonal Antibodies Manufacturers and Market Share, 2021-2026
4.4.1 United States Based Anti-IL-23 p19 Monoclonal Antibodies Manufacturers, Headquarters and Production Site (States, Country)
4.4.2 United States Based Manufacturers Anti-IL-23 p19 Monoclonal Antibodies Production Value (2021-2026)
4.4.3 United States Based Manufacturers Anti-IL-23 p19 Monoclonal Antibodies Production (2021-2026)
4.5 China Based Anti-IL-23 p19 Monoclonal Antibodies Manufacturers and Market Share
4.5.1 China Based Anti-IL-23 p19 Monoclonal Antibodies Manufacturers, Headquarters and Production Site (Province, Country)
4.5.2 China Based Manufacturers Anti-IL-23 p19 Monoclonal Antibodies Production Value (2021-2026)
4.5.3 China Based Manufacturers Anti-IL-23 p19 Monoclonal Antibodies Production (2021-2026)
4.6 Rest of World Based Anti-IL-23 p19 Monoclonal Antibodies Manufacturers and Market Share, 2021-2026
4.6.1 Rest of World Based Anti-IL-23 p19 Monoclonal Antibodies Manufacturers, Headquarters and Production Site (State, Country)
4.6.2 Rest of World Based Manufacturers Anti-IL-23 p19 Monoclonal Antibodies Production Value (2021-2026)
4.6.3 Rest of World Based Manufacturers Anti-IL-23 p19 Monoclonal Antibodies Production (2021-2026)
5 MARKET ANALYSIS BY INDICATION
5.1 World Anti-IL-23 p19 Monoclonal Antibodies Market Size Overview by Indication: 2021 VS 2025 VS 2032
5.2 Segment Introduction by Indication
5.2.1 Plaque Psoriasis
5.2.2 Psoriatic Arthritis
5.2.3 Crohn's Disease
5.2.4 Ulcerative Colitis
5.2.5 Others
5.3 Market Segment by Indication
5.3.1 World Anti-IL-23 p19 Monoclonal Antibodies Production by Indication (2021-2032)
5.3.2 World Anti-IL-23 p19 Monoclonal Antibodies Production Value by Indication (2021-2032)
5.3.3 World Anti-IL-23 p19 Monoclonal Antibodies Average Price by Indication (2021-2032)
6 MARKET ANALYSIS BY MOLECULE TYPE
6.1 World Anti-IL-23 p19 Monoclonal Antibodies Market Size Overview by Molecule Type: 2021 VS 2025 VS 2032
6.2 Segment Introduction by Molecule Type
6.2.1 Humanized IgG Monoclonal Antibodies
6.2.2 Fully Human IgG Monoclonal Antibodies
6.2.3 Fc-engineered or Long-acting Antibodies
6.2.4 Others
6.3 Market Segment by Molecule Type
6.3.1 World Anti-IL-23 p19 Monoclonal Antibodies Production by Molecule Type (2021-2032)
6.3.2 World Anti-IL-23 p19 Monoclonal Antibodies Production Value by Molecule Type (2021-2032)
6.3.3 World Anti-IL-23 p19 Monoclonal Antibodies Average Price by Molecule Type (2021-2032)
7 MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
7.1 World Anti-IL-23 p19 Monoclonal Antibodies Market Size Overview by Route of Administration: 2021 VS 2025 VS 2032
7.2 Segment Introduction by Route of Administration
7.2.1 Subcutaneous Injection
7.2.2 Intravenous Induction plus Subcutaneous Maintenance
7.2.3 Intravenous Injection
7.2.4 Others
7.3 Market Segment by Route of Administration
7.3.1 World Anti-IL-23 p19 Monoclonal Antibodies Production by Route of Administration (2021-2032)
7.3.2 World Anti-IL-23 p19 Monoclonal Antibodies Production Value by Route of Administration (2021-2032)
7.3.3 World Anti-IL-23 p19 Monoclonal Antibodies Average Price by Route of Administration (2021-2032)
8 MARKET ANALYSIS BY APPLICATION
8.1 World Anti-IL-23 p19 Monoclonal Antibodies Market Size Overview by Application: 2021 VS 2025 VS 2032
8.2 Segment Introduction by Application
8.2.1 Hospitals
8.2.2 Specialist Clinics
8.2.3 Infusion Centers
8.2.4 Specialty Pharmacies
8.2.5 Retail and DTP Pharmacies
8.2.6 Others
8.3 Market Segment by Application
8.3.1 World Anti-IL-23 p19 Monoclonal Antibodies Production by Application (2021-2032)
8.3.2 World Anti-IL-23 p19 Monoclonal Antibodies Production Value by Application (2021-2032)
8.3.3 World Anti-IL-23 p19 Monoclonal Antibodies Average Price by Application (2021-2032)
9 COMPANY PROFILES
9.1 AbbVie Inc.
9.1.1 AbbVie Inc. Details
9.1.2 AbbVie Inc. Major Business
9.1.3 AbbVie Inc. Anti-IL-23 p19 Monoclonal Antibodies Product and Services
9.1.4 AbbVie Inc. Anti-IL-23 p19 Monoclonal Antibodies Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.1.5 AbbVie Inc. Recent Developments/Updates
9.1.6 AbbVie Inc. Competitive Strengths & Weaknesses
9.2 Johnson & Johnson
9.2.1 Johnson & Johnson Details
9.2.2 Johnson & Johnson Major Business
9.2.3 Johnson & Johnson Anti-IL-23 p19 Monoclonal Antibodies Product and Services
9.2.4 Johnson & Johnson Anti-IL-23 p19 Monoclonal Antibodies Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.2.5 Johnson & Johnson Recent Developments/Updates
9.2.6 Johnson & Johnson Competitive Strengths & Weaknesses
9.3 Eli Lilly and Company
9.3.1 Eli Lilly and Company Details
9.3.2 Eli Lilly and Company Major Business
9.3.3 Eli Lilly and Company Anti-IL-23 p19 Monoclonal Antibodies Product and Services
9.3.4 Eli Lilly and Company Anti-IL-23 p19 Monoclonal Antibodies Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.3.5 Eli Lilly and Company Recent Developments/Updates
9.3.6 Eli Lilly and Company Competitive Strengths & Weaknesses
9.4 Sun Pharmaceutical Industries Limited
9.4.1 Sun Pharmaceutical Industries Limited Details
9.4.2 Sun Pharmaceutical Industries Limited Major Business
9.4.3 Sun Pharmaceutical Industries Limited Anti-IL-23 p19 Monoclonal Antibodies Product and Services
9.4.4 Sun Pharmaceutical Industries Limited Anti-IL-23 p19 Monoclonal Antibodies Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.4.5 Sun Pharmaceutical Industries Limited Recent Developments/Updates
9.4.6 Sun Pharmaceutical Industries Limited Competitive Strengths & Weaknesses
9.5 Innovent Biologics, Inc.
9.5.1 Innovent Biologics, Inc. Details
9.5.2 Innovent Biologics, Inc. Major Business
9.5.3 Innovent Biologics, Inc. Anti-IL-23 p19 Monoclonal Antibodies Product and Services
9.5.4 Innovent Biologics, Inc. Anti-IL-23 p19 Monoclonal Antibodies Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.5.5 Innovent Biologics, Inc. Recent Developments/Updates
9.5.6 Innovent Biologics, Inc. Competitive Strengths & Weaknesses
9.6 Hansoh Pharmaceutical Group Company Limited
9.6.1 Hansoh Pharmaceutical Group Company Limited Details
9.6.2 Hansoh Pharmaceutical Group Company Limited Major Business
9.6.3 Hansoh Pharmaceutical Group Company Limited Anti-IL-23 p19 Monoclonal Antibodies Product and Services
9.6.4 Hansoh Pharmaceutical Group Company Limited Anti-IL-23 p19 Monoclonal Antibodies Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.6.5 Hansoh Pharmaceutical Group Company Limited Recent Developments/Updates
9.6.6 Hansoh Pharmaceutical Group Company Limited Competitive Strengths & Weaknesses
9.7 SUN Pharmaceuticals Industries Europe B.V.
9.7.1 SUN Pharmaceuticals Industries Europe B.V. Details
9.7.2 SUN Pharmaceuticals Industries Europe B.V. Major Business
9.7.3 SUN Pharmaceuticals Industries Europe B.V. Anti-IL-23 p19 Monoclonal Antibodies Product and Services
9.7.4 SUN Pharmaceuticals Industries Europe B.V. Anti-IL-23 p19 Monoclonal Antibodies Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.7.5 SUN Pharmaceuticals Industries Europe B.V. Recent Developments/Updates
9.7.6 SUN Pharmaceuticals Industries Europe B.V. Competitive Strengths & Weaknesses
9.8 Industrias Farmac?uticas Almirall, S.A.
9.8.1 Industrias Farmac?uticas Almirall, S.A. Details
9.8.2 Industrias Farmac?uticas Almirall, S.A. Major Business
9.8.3 Industrias Farmac?uticas Almirall, S.A. Anti-IL-23 p19 Monoclonal Antibodies Product and Services
9.8.4 Industrias Farmac?uticas Almirall, S.A. Anti-IL-23 p19 Monoclonal Antibodies Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.8.5 Industrias Farmac?uticas Almirall, S.A. Recent Developments/Updates
9.8.6 Industrias Farmac?uticas Almirall, S.A. Competitive Strengths & Weaknesses
10 INDUSTRY CHAIN ANALYSIS
10.1 Anti-IL-23 p19 Monoclonal Antibodies Industry Chain
10.2 Anti-IL-23 p19 Monoclonal Antibodies Upstream Analysis
10.2.1 Anti-IL-23 p19 Monoclonal Antibodies Core Raw Materials
10.2.2 Main Manufacturers of Anti-IL-23 p19 Monoclonal Antibodies Core Raw Materials
10.3 Midstream Analysis
10.4 Downstream Analysis
10.5 Anti-IL-23 p19 Monoclonal Antibodies Production Mode
10.6 Anti-IL-23 p19 Monoclonal Antibodies Procurement Model
10.7 Anti-IL-23 p19 Monoclonal Antibodies Industry Sales Model and Sales Channels
10.7.1 Anti-IL-23 p19 Monoclonal Antibodies Sales Model
10.7.2 Anti-IL-23 p19 Monoclonal Antibodies Typical Distributors
11 RESEARCH FINDINGS AND CONCLUSION
12 APPENDIX
12.1 Methodology
12.2 Research Process and Data Source
12.3 Disclaimer
1.1 Anti-IL-23 p19 Monoclonal Antibodies Introduction
1.2 World Anti-IL-23 p19 Monoclonal Antibodies Supply & Forecast
1.2.1 World Anti-IL-23 p19 Monoclonal Antibodies Production Value (2021 & 2025 & 2032)
1.2.2 World Anti-IL-23 p19 Monoclonal Antibodies Production (2021-2032)
1.2.3 World Anti-IL-23 p19 Monoclonal Antibodies Pricing Trends (2021-2032)
1.3 World Anti-IL-23 p19 Monoclonal Antibodies Production by Region (Based on Production Site)
1.3.1 World Anti-IL-23 p19 Monoclonal Antibodies Production Value by Region (2021-2032)
1.3.2 World Anti-IL-23 p19 Monoclonal Antibodies Production by Region (2021-2032)
1.3.3 World Anti-IL-23 p19 Monoclonal Antibodies Average Price by Region (2021-2032)
1.3.4 North America Anti-IL-23 p19 Monoclonal Antibodies Production (2021-2032)
1.3.5 Europe Anti-IL-23 p19 Monoclonal Antibodies Production (2021-2032)
1.3.6 China Anti-IL-23 p19 Monoclonal Antibodies Production (2021-2032)
1.3.7 Japan Anti-IL-23 p19 Monoclonal Antibodies Production (2021-2032)
1.4 Market Drivers, Restraints and Trends
1.4.1 Anti-IL-23 p19 Monoclonal Antibodies Market Drivers
1.4.2 Factors Affecting Demand
1.4.3 Anti-IL-23 p19 Monoclonal Antibodies Major Market Trends
2 DEMAND SUMMARY
2.1 World Anti-IL-23 p19 Monoclonal Antibodies Demand (2021-2032)
2.2 World Anti-IL-23 p19 Monoclonal Antibodies Consumption by Region
2.2.1 World Anti-IL-23 p19 Monoclonal Antibodies Consumption by Region (2021-2026)
2.2.2 World Anti-IL-23 p19 Monoclonal Antibodies Consumption Forecast by Region (2027-2032)
2.3 United States Anti-IL-23 p19 Monoclonal Antibodies Consumption (2021-2032)
2.4 China Anti-IL-23 p19 Monoclonal Antibodies Consumption (2021-2032)
2.5 Europe Anti-IL-23 p19 Monoclonal Antibodies Consumption (2021-2032)
2.6 Japan Anti-IL-23 p19 Monoclonal Antibodies Consumption (2021-2032)
2.7 South Korea Anti-IL-23 p19 Monoclonal Antibodies Consumption (2021-2032)
2.8 ASEAN Anti-IL-23 p19 Monoclonal Antibodies Consumption (2021-2032)
2.9 India Anti-IL-23 p19 Monoclonal Antibodies Consumption (2021-2032)
3 WORLD MANUFACTURERS COMPETITIVE ANALYSIS
3.1 World Anti-IL-23 p19 Monoclonal Antibodies Production Value by Manufacturer (2021-2026)
3.2 World Anti-IL-23 p19 Monoclonal Antibodies Production by Manufacturer (2021-2026)
3.3 World Anti-IL-23 p19 Monoclonal Antibodies Average Price by Manufacturer (2021-2026)
3.4 Anti-IL-23 p19 Monoclonal Antibodies Company Evaluation Quadrant
3.5 Industry Rank and Concentration Rate (CR)
3.5.1 Global Anti-IL-23 p19 Monoclonal Antibodies Industry Rank of Major Manufacturers
3.5.2 Global Concentration Ratios (CR4) for Anti-IL-23 p19 Monoclonal Antibodies in 2025
3.5.3 Global Concentration Ratios (CR8) for Anti-IL-23 p19 Monoclonal Antibodies in 2025
3.6 Anti-IL-23 p19 Monoclonal Antibodies Market: Overall Company Footprint Analysis
3.6.1 Anti-IL-23 p19 Monoclonal Antibodies Market: Region Footprint
3.6.2 Anti-IL-23 p19 Monoclonal Antibodies Market: Company Product Type Footprint
3.6.3 Anti-IL-23 p19 Monoclonal Antibodies Market: Company Product Application Footprint
3.7 Competitive Environment
3.7.1 Historical Structure of the Industry
3.7.2 Barriers of Market Entry
3.7.3 Factors of Competition
3.8 New Entrant and Capacity Expansion Plans
3.9 Mergers, Acquisition, Agreements, and Collaborations
4 UNITED STATES VS CHINA VS REST OF THE WORLD
4.1 United States VS China: Anti-IL-23 p19 Monoclonal Antibodies Production Value Comparison
4.1.1 United States VS China: Anti-IL-23 p19 Monoclonal Antibodies Production Value Comparison (2021 & 2025 & 2032)
4.1.2 United States VS China: Anti-IL-23 p19 Monoclonal Antibodies Production Value Market Share Comparison (2021 & 2025 & 2032)
4.2 United States VS China: Anti-IL-23 p19 Monoclonal Antibodies Production Comparison
4.2.1 United States VS China: Anti-IL-23 p19 Monoclonal Antibodies Production Comparison (2021 & 2025 & 2032)
4.2.2 United States VS China: Anti-IL-23 p19 Monoclonal Antibodies Production Market Share Comparison (2021 & 2025 & 2032)
4.3 United States VS China: Anti-IL-23 p19 Monoclonal Antibodies Consumption Comparison
4.3.1 United States VS China: Anti-IL-23 p19 Monoclonal Antibodies Consumption Comparison (2021 & 2025 & 2032)
4.3.2 United States VS China: Anti-IL-23 p19 Monoclonal Antibodies Consumption Market Share Comparison (2021 & 2025 & 2032)
4.4 United States Based Anti-IL-23 p19 Monoclonal Antibodies Manufacturers and Market Share, 2021-2026
4.4.1 United States Based Anti-IL-23 p19 Monoclonal Antibodies Manufacturers, Headquarters and Production Site (States, Country)
4.4.2 United States Based Manufacturers Anti-IL-23 p19 Monoclonal Antibodies Production Value (2021-2026)
4.4.3 United States Based Manufacturers Anti-IL-23 p19 Monoclonal Antibodies Production (2021-2026)
4.5 China Based Anti-IL-23 p19 Monoclonal Antibodies Manufacturers and Market Share
4.5.1 China Based Anti-IL-23 p19 Monoclonal Antibodies Manufacturers, Headquarters and Production Site (Province, Country)
4.5.2 China Based Manufacturers Anti-IL-23 p19 Monoclonal Antibodies Production Value (2021-2026)
4.5.3 China Based Manufacturers Anti-IL-23 p19 Monoclonal Antibodies Production (2021-2026)
4.6 Rest of World Based Anti-IL-23 p19 Monoclonal Antibodies Manufacturers and Market Share, 2021-2026
4.6.1 Rest of World Based Anti-IL-23 p19 Monoclonal Antibodies Manufacturers, Headquarters and Production Site (State, Country)
4.6.2 Rest of World Based Manufacturers Anti-IL-23 p19 Monoclonal Antibodies Production Value (2021-2026)
4.6.3 Rest of World Based Manufacturers Anti-IL-23 p19 Monoclonal Antibodies Production (2021-2026)
5 MARKET ANALYSIS BY INDICATION
5.1 World Anti-IL-23 p19 Monoclonal Antibodies Market Size Overview by Indication: 2021 VS 2025 VS 2032
5.2 Segment Introduction by Indication
5.2.1 Plaque Psoriasis
5.2.2 Psoriatic Arthritis
5.2.3 Crohn's Disease
5.2.4 Ulcerative Colitis
5.2.5 Others
5.3 Market Segment by Indication
5.3.1 World Anti-IL-23 p19 Monoclonal Antibodies Production by Indication (2021-2032)
5.3.2 World Anti-IL-23 p19 Monoclonal Antibodies Production Value by Indication (2021-2032)
5.3.3 World Anti-IL-23 p19 Monoclonal Antibodies Average Price by Indication (2021-2032)
6 MARKET ANALYSIS BY MOLECULE TYPE
6.1 World Anti-IL-23 p19 Monoclonal Antibodies Market Size Overview by Molecule Type: 2021 VS 2025 VS 2032
6.2 Segment Introduction by Molecule Type
6.2.1 Humanized IgG Monoclonal Antibodies
6.2.2 Fully Human IgG Monoclonal Antibodies
6.2.3 Fc-engineered or Long-acting Antibodies
6.2.4 Others
6.3 Market Segment by Molecule Type
6.3.1 World Anti-IL-23 p19 Monoclonal Antibodies Production by Molecule Type (2021-2032)
6.3.2 World Anti-IL-23 p19 Monoclonal Antibodies Production Value by Molecule Type (2021-2032)
6.3.3 World Anti-IL-23 p19 Monoclonal Antibodies Average Price by Molecule Type (2021-2032)
7 MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
7.1 World Anti-IL-23 p19 Monoclonal Antibodies Market Size Overview by Route of Administration: 2021 VS 2025 VS 2032
7.2 Segment Introduction by Route of Administration
7.2.1 Subcutaneous Injection
7.2.2 Intravenous Induction plus Subcutaneous Maintenance
7.2.3 Intravenous Injection
7.2.4 Others
7.3 Market Segment by Route of Administration
7.3.1 World Anti-IL-23 p19 Monoclonal Antibodies Production by Route of Administration (2021-2032)
7.3.2 World Anti-IL-23 p19 Monoclonal Antibodies Production Value by Route of Administration (2021-2032)
7.3.3 World Anti-IL-23 p19 Monoclonal Antibodies Average Price by Route of Administration (2021-2032)
8 MARKET ANALYSIS BY APPLICATION
8.1 World Anti-IL-23 p19 Monoclonal Antibodies Market Size Overview by Application: 2021 VS 2025 VS 2032
8.2 Segment Introduction by Application
8.2.1 Hospitals
8.2.2 Specialist Clinics
8.2.3 Infusion Centers
8.2.4 Specialty Pharmacies
8.2.5 Retail and DTP Pharmacies
8.2.6 Others
8.3 Market Segment by Application
8.3.1 World Anti-IL-23 p19 Monoclonal Antibodies Production by Application (2021-2032)
8.3.2 World Anti-IL-23 p19 Monoclonal Antibodies Production Value by Application (2021-2032)
8.3.3 World Anti-IL-23 p19 Monoclonal Antibodies Average Price by Application (2021-2032)
9 COMPANY PROFILES
9.1 AbbVie Inc.
9.1.1 AbbVie Inc. Details
9.1.2 AbbVie Inc. Major Business
9.1.3 AbbVie Inc. Anti-IL-23 p19 Monoclonal Antibodies Product and Services
9.1.4 AbbVie Inc. Anti-IL-23 p19 Monoclonal Antibodies Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.1.5 AbbVie Inc. Recent Developments/Updates
9.1.6 AbbVie Inc. Competitive Strengths & Weaknesses
9.2 Johnson & Johnson
9.2.1 Johnson & Johnson Details
9.2.2 Johnson & Johnson Major Business
9.2.3 Johnson & Johnson Anti-IL-23 p19 Monoclonal Antibodies Product and Services
9.2.4 Johnson & Johnson Anti-IL-23 p19 Monoclonal Antibodies Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.2.5 Johnson & Johnson Recent Developments/Updates
9.2.6 Johnson & Johnson Competitive Strengths & Weaknesses
9.3 Eli Lilly and Company
9.3.1 Eli Lilly and Company Details
9.3.2 Eli Lilly and Company Major Business
9.3.3 Eli Lilly and Company Anti-IL-23 p19 Monoclonal Antibodies Product and Services
9.3.4 Eli Lilly and Company Anti-IL-23 p19 Monoclonal Antibodies Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.3.5 Eli Lilly and Company Recent Developments/Updates
9.3.6 Eli Lilly and Company Competitive Strengths & Weaknesses
9.4 Sun Pharmaceutical Industries Limited
9.4.1 Sun Pharmaceutical Industries Limited Details
9.4.2 Sun Pharmaceutical Industries Limited Major Business
9.4.3 Sun Pharmaceutical Industries Limited Anti-IL-23 p19 Monoclonal Antibodies Product and Services
9.4.4 Sun Pharmaceutical Industries Limited Anti-IL-23 p19 Monoclonal Antibodies Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.4.5 Sun Pharmaceutical Industries Limited Recent Developments/Updates
9.4.6 Sun Pharmaceutical Industries Limited Competitive Strengths & Weaknesses
9.5 Innovent Biologics, Inc.
9.5.1 Innovent Biologics, Inc. Details
9.5.2 Innovent Biologics, Inc. Major Business
9.5.3 Innovent Biologics, Inc. Anti-IL-23 p19 Monoclonal Antibodies Product and Services
9.5.4 Innovent Biologics, Inc. Anti-IL-23 p19 Monoclonal Antibodies Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.5.5 Innovent Biologics, Inc. Recent Developments/Updates
9.5.6 Innovent Biologics, Inc. Competitive Strengths & Weaknesses
9.6 Hansoh Pharmaceutical Group Company Limited
9.6.1 Hansoh Pharmaceutical Group Company Limited Details
9.6.2 Hansoh Pharmaceutical Group Company Limited Major Business
9.6.3 Hansoh Pharmaceutical Group Company Limited Anti-IL-23 p19 Monoclonal Antibodies Product and Services
9.6.4 Hansoh Pharmaceutical Group Company Limited Anti-IL-23 p19 Monoclonal Antibodies Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.6.5 Hansoh Pharmaceutical Group Company Limited Recent Developments/Updates
9.6.6 Hansoh Pharmaceutical Group Company Limited Competitive Strengths & Weaknesses
9.7 SUN Pharmaceuticals Industries Europe B.V.
9.7.1 SUN Pharmaceuticals Industries Europe B.V. Details
9.7.2 SUN Pharmaceuticals Industries Europe B.V. Major Business
9.7.3 SUN Pharmaceuticals Industries Europe B.V. Anti-IL-23 p19 Monoclonal Antibodies Product and Services
9.7.4 SUN Pharmaceuticals Industries Europe B.V. Anti-IL-23 p19 Monoclonal Antibodies Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.7.5 SUN Pharmaceuticals Industries Europe B.V. Recent Developments/Updates
9.7.6 SUN Pharmaceuticals Industries Europe B.V. Competitive Strengths & Weaknesses
9.8 Industrias Farmac?uticas Almirall, S.A.
9.8.1 Industrias Farmac?uticas Almirall, S.A. Details
9.8.2 Industrias Farmac?uticas Almirall, S.A. Major Business
9.8.3 Industrias Farmac?uticas Almirall, S.A. Anti-IL-23 p19 Monoclonal Antibodies Product and Services
9.8.4 Industrias Farmac?uticas Almirall, S.A. Anti-IL-23 p19 Monoclonal Antibodies Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.8.5 Industrias Farmac?uticas Almirall, S.A. Recent Developments/Updates
9.8.6 Industrias Farmac?uticas Almirall, S.A. Competitive Strengths & Weaknesses
10 INDUSTRY CHAIN ANALYSIS
10.1 Anti-IL-23 p19 Monoclonal Antibodies Industry Chain
10.2 Anti-IL-23 p19 Monoclonal Antibodies Upstream Analysis
10.2.1 Anti-IL-23 p19 Monoclonal Antibodies Core Raw Materials
10.2.2 Main Manufacturers of Anti-IL-23 p19 Monoclonal Antibodies Core Raw Materials
10.3 Midstream Analysis
10.4 Downstream Analysis
10.5 Anti-IL-23 p19 Monoclonal Antibodies Production Mode
10.6 Anti-IL-23 p19 Monoclonal Antibodies Procurement Model
10.7 Anti-IL-23 p19 Monoclonal Antibodies Industry Sales Model and Sales Channels
10.7.1 Anti-IL-23 p19 Monoclonal Antibodies Sales Model
10.7.2 Anti-IL-23 p19 Monoclonal Antibodies Typical Distributors
11 RESEARCH FINDINGS AND CONCLUSION
12 APPENDIX
12.1 Methodology
12.2 Research Process and Data Source
12.3 Disclaimer
LIST OF TABLES
Table 1. World Anti-IL-23 p19 Monoclonal Antibodies Production Value by Region (2021, 2025 and 2032) & (USD Million)
Table 2. World Anti-IL-23 p19 Monoclonal Antibodies Production Value by Region (2021-2026) & (USD Million)
Table 3. World Anti-IL-23 p19 Monoclonal Antibodies Production Value by Region (2027-2032) & (USD Million)
Table 4. World Anti-IL-23 p19 Monoclonal Antibodies Production Value Market Share by Region (2021-2026)
Table 5. World Anti-IL-23 p19 Monoclonal Antibodies Production Value Market Share by Region (2027-2032)
Table 6. World Anti-IL-23 p19 Monoclonal Antibodies Production by Region (2021-2026) & (Unit)
Table 7. World Anti-IL-23 p19 Monoclonal Antibodies Production by Region (2027-2032) & (Unit)
Table 8. World Anti-IL-23 p19 Monoclonal Antibodies Production Market Share by Region (2021-2026)
Table 9. World Anti-IL-23 p19 Monoclonal Antibodies Production Market Share by Region (2027-2032)
Table 10. World Anti-IL-23 p19 Monoclonal Antibodies Average Price by Region (2021-2026) & (US$/Unit)
Table 11. World Anti-IL-23 p19 Monoclonal Antibodies Average Price by Region (2027-2032) & (US$/Unit)
Table 12. Anti-IL-23 p19 Monoclonal Antibodies Major Market Trends
Table 13. World Anti-IL-23 p19 Monoclonal Antibodies Consumption Growth Rate Forecast by Region (2021 & 2025 & 2032) & (Unit)
Table 14. World Anti-IL-23 p19 Monoclonal Antibodies Consumption by Region (2021-2026) & (Unit)
Table 15. World Anti-IL-23 p19 Monoclonal Antibodies Consumption Forecast by Region (2027-2032) & (Unit)
Table 16. World Anti-IL-23 p19 Monoclonal Antibodies Production Value by Manufacturer (2021-2026) & (USD Million)
Table 17. Production Value Market Share of Key Anti-IL-23 p19 Monoclonal Antibodies Producers in 2025
Table 18. World Anti-IL-23 p19 Monoclonal Antibodies Production by Manufacturer (2021-2026) & (Unit)
Table 19. Production Market Share of Key Anti-IL-23 p19 Monoclonal Antibodies Producers in 2025
Table 20. World Anti-IL-23 p19 Monoclonal Antibodies Average Price by Manufacturer (2021-2026) & (US$/Unit)
Table 21. Global Anti-IL-23 p19 Monoclonal Antibodies Company Evaluation Quadrant
Table 22. World Anti-IL-23 p19 Monoclonal Antibodies Industry Rank of Major Manufacturers, Based on Production Value in 2025
Table 23. Head Office and Anti-IL-23 p19 Monoclonal Antibodies Production Site of Key Manufacturer
Table 24. Anti-IL-23 p19 Monoclonal Antibodies Market: Company Product Type Footprint
Table 25. Anti-IL-23 p19 Monoclonal Antibodies Market: Company Product Application Footprint
Table 26. Anti-IL-23 p19 Monoclonal Antibodies Competitive Factors
Table 27. Anti-IL-23 p19 Monoclonal Antibodies New Entrant and Capacity Expansion Plans
Table 28. Anti-IL-23 p19 Monoclonal Antibodies Mergers & Acquisitions Activity
Table 29. United States VS China Anti-IL-23 p19 Monoclonal Antibodies Production Value Comparison, (2021 & 2025 & 2032) & (USD Million)
Table 30. United States VS China Anti-IL-23 p19 Monoclonal Antibodies Production Comparison, (2021 & 2025 & 2032) & (Unit)
Table 31. United States VS China Anti-IL-23 p19 Monoclonal Antibodies Consumption Comparison, (2021 & 2025 & 2032) & (Unit)
Table 32. United States Based Anti-IL-23 p19 Monoclonal Antibodies Manufacturers, Headquarters and Production Site (States, Country)
Table 33. United States Based Manufacturers Anti-IL-23 p19 Monoclonal Antibodies Production Value, (2021-2026) & (USD Million)
Table 34. United States Based Manufacturers Anti-IL-23 p19 Monoclonal Antibodies Production Value Market Share (2021-2026)
Table 35. United States Based Manufacturers Anti-IL-23 p19 Monoclonal Antibodies Production (2021-2026) & (Unit)
Table 36. United States Based Manufacturers Anti-IL-23 p19 Monoclonal Antibodies Production Market Share (2021-2026)
Table 37. China Based Anti-IL-23 p19 Monoclonal Antibodies Manufacturers, Headquarters and Production Site (Province, Country)
Table 38. China Based Manufacturers Anti-IL-23 p19 Monoclonal Antibodies Production Value, (2021-2026) & (USD Million)
Table 39. China Based Manufacturers Anti-IL-23 p19 Monoclonal Antibodies Production Value Market Share (2021-2026)
Table 40. China Based Manufacturers Anti-IL-23 p19 Monoclonal Antibodies Production, (2021-2026) & (Unit)
Table 41. China Based Manufacturers Anti-IL-23 p19 Monoclonal Antibodies Production Market Share (2021-2026)
Table 42. Rest of World Based Anti-IL-23 p19 Monoclonal Antibodies Manufacturers, Headquarters and Production Site (State, Country)
Table 43. Rest of World Based Manufacturers Anti-IL-23 p19 Monoclonal Antibodies Production Value, (2021-2026) & (USD Million)
Table 44. Rest of World Based Manufacturers Anti-IL-23 p19 Monoclonal Antibodies Production Value Market Share (2021-2026)
Table 45. Rest of World Based Manufacturers Anti-IL-23 p19 Monoclonal Antibodies Production, (2021-2026) & (Unit)
Table 46. Rest of World Based Manufacturers Anti-IL-23 p19 Monoclonal Antibodies Production Market Share (2021-2026)
Table 47. World Anti-IL-23 p19 Monoclonal Antibodies Production Value by Indication, (USD Million), 2021 & 2025 & 2032
Table 48. World Anti-IL-23 p19 Monoclonal Antibodies Production by Indication (2021-2026) & (Unit)
Table 49. World Anti-IL-23 p19 Monoclonal Antibodies Production by Indication (2027-2032) & (Unit)
Table 50. World Anti-IL-23 p19 Monoclonal Antibodies Production Value by Indication (2021-2026) & (USD Million)
Table 51. World Anti-IL-23 p19 Monoclonal Antibodies Production Value by Indication (2027-2032) & (USD Million)
Table 52. World Anti-IL-23 p19 Monoclonal Antibodies Average Price by Indication (2021-2026) & (US$/Unit)
Table 53. World Anti-IL-23 p19 Monoclonal Antibodies Average Price by Indication (2027-2032) & (US$/Unit)
Table 54. World Anti-IL-23 p19 Monoclonal Antibodies Production Value by Molecule Type, (USD Million), 2021 & 2025 & 2032
Table 55. World Anti-IL-23 p19 Monoclonal Antibodies Production by Molecule Type (2021-2026) & (Unit)
Table 56. World Anti-IL-23 p19 Monoclonal Antibodies Production by Molecule Type (2027-2032) & (Unit)
Table 57. World Anti-IL-23 p19 Monoclonal Antibodies Production Value by Molecule Type (2021-2026) & (USD Million)
Table 58. World Anti-IL-23 p19 Monoclonal Antibodies Production Value by Molecule Type (2027-2032) & (USD Million)
Table 59. World Anti-IL-23 p19 Monoclonal Antibodies Average Price by Molecule Type (2021-2026) & (US$/Unit)
Table 60. World Anti-IL-23 p19 Monoclonal Antibodies Average Price by Molecule Type (2027-2032) & (US$/Unit)
Table 61. World Anti-IL-23 p19 Monoclonal Antibodies Production Value by Route of Administration, (USD Million), 2021 & 2025 & 2032
Table 62. World Anti-IL-23 p19 Monoclonal Antibodies Production by Route of Administration (2021-2026) & (Unit)
Table 63. World Anti-IL-23 p19 Monoclonal Antibodies Production by Route of Administration (2027-2032) & (Unit)
Table 64. World Anti-IL-23 p19 Monoclonal Antibodies Production Value by Route of Administration (2021-2026) & (USD Million)
Table 65. World Anti-IL-23 p19 Monoclonal Antibodies Production Value by Route of Administration (2027-2032) & (USD Million)
Table 66. World Anti-IL-23 p19 Monoclonal Antibodies Average Price by Route of Administration (2021-2026) & (US$/Unit)
Table 67. World Anti-IL-23 p19 Monoclonal Antibodies Average Price by Route of Administration (2027-2032) & (US$/Unit)
Table 68. World Anti-IL-23 p19 Monoclonal Antibodies Production Value by Application, (USD Million), 2021 & 2025 & 2032
Table 69. World Anti-IL-23 p19 Monoclonal Antibodies Production by Application (2021-2026) & (Unit)
Table 70. World Anti-IL-23 p19 Monoclonal Antibodies Production by Application (2027-2032) & (Unit)
Table 71. World Anti-IL-23 p19 Monoclonal Antibodies Production Value by Application (2021-2026) & (USD Million)
Table 72. World Anti-IL-23 p19 Monoclonal Antibodies Production Value by Application (2027-2032) & (USD Million)
Table 73. World Anti-IL-23 p19 Monoclonal Antibodies Average Price by Application (2021-2026) & (US$/Unit)
Table 74. World Anti-IL-23 p19 Monoclonal Antibodies Average Price by Application (2027-2032) & (US$/Unit)
Table 75. AbbVie Inc. Basic Information, Manufacturing Base and Competitors
Table 76. AbbVie Inc. Major Business
Table 77. AbbVie Inc. Anti-IL-23 p19 Monoclonal Antibodies Product and Services
Table 78. AbbVie Inc. Anti-IL-23 p19 Monoclonal Antibodies Production (Unit), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 79. AbbVie Inc. Recent Developments/Updates
Table 80. AbbVie Inc. Competitive Strengths & Weaknesses
Table 81. Johnson & Johnson Basic Information, Manufacturing Base and Competitors
Table 82. Johnson & Johnson Major Business
Table 83. Johnson & Johnson Anti-IL-23 p19 Monoclonal Antibodies Product and Services
Table 84. Johnson & Johnson Anti-IL-23 p19 Monoclonal Antibodies Production (Unit), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 85. Johnson & Johnson Recent Developments/Updates
Table 86. Johnson & Johnson Competitive Strengths & Weaknesses
Table 87. Eli Lilly and Company Basic Information, Manufacturing Base and Competitors
Table 88. Eli Lilly and Company Major Business
Table 89. Eli Lilly and Company Anti-IL-23 p19 Monoclonal Antibodies Product and Services
Table 90. Eli Lilly and Company Anti-IL-23 p19 Monoclonal Antibodies Production (Unit), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 91. Eli Lilly and Company Recent Developments/Updates
Table 92. Eli Lilly and Company Competitive Strengths & Weaknesses
Table 93. Sun Pharmaceutical Industries Limited Basic Information, Manufacturing Base and Competitors
Table 94. Sun Pharmaceutical Industries Limited Major Business
Table 95. Sun Pharmaceutical Industries Limited Anti-IL-23 p19 Monoclonal Antibodies Product and Services
Table 96. Sun Pharmaceutical Industries Limited Anti-IL-23 p19 Monoclonal Antibodies Production (Unit), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 97. Sun Pharmaceutical Industries Limited Recent Developments/Updates
Table 98. Sun Pharmaceutical Industries Limited Competitive Strengths & Weaknesses
Table 99. Innovent Biologics, Inc. Basic Information, Manufacturing Base and Competitors
Table 100. Innovent Biologics, Inc. Major Business
Table 101. Innovent Biologics, Inc. Anti-IL-23 p19 Monoclonal Antibodies Product and Services
Table 102. Innovent Biologics, Inc. Anti-IL-23 p19 Monoclonal Antibodies Production (Unit), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 103. Innovent Biologics, Inc. Recent Developments/Updates
Table 104. Innovent Biologics, Inc. Competitive Strengths & Weaknesses
Table 105. Hansoh Pharmaceutical Group Company Limited Basic Information, Manufacturing Base and Competitors
Table 106. Hansoh Pharmaceutical Group Company Limited Major Business
Table 107. Hansoh Pharmaceutical Group Company Limited Anti-IL-23 p19 Monoclonal Antibodies Product and Services
Table 108. Hansoh Pharmaceutical Group Company Limited Anti-IL-23 p19 Monoclonal Antibodies Production (Unit), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 109. Hansoh Pharmaceutical Group Company Limited Recent Developments/Updates
Table 110. Hansoh Pharmaceutical Group Company Limited Competitive Strengths & Weaknesses
Table 111. SUN Pharmaceuticals Industries Europe B.V. Basic Information, Manufacturing Base and Competitors
Table 112. SUN Pharmaceuticals Industries Europe B.V. Major Business
Table 113. SUN Pharmaceuticals Industries Europe B.V. Anti-IL-23 p19 Monoclonal Antibodies Product and Services
Table 114. SUN Pharmaceuticals Industries Europe B.V. Anti-IL-23 p19 Monoclonal Antibodies Production (Unit), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 115. SUN Pharmaceuticals Industries Europe B.V. Recent Developments/Updates
Table 116. SUN Pharmaceuticals Industries Europe B.V. Competitive Strengths & Weaknesses
Table 117. Industrias Farmac?uticas Almirall, S.A. Basic Information, Manufacturing Base and Competitors
Table 118. Industrias Farmac?uticas Almirall, S.A. Major Business
Table 119. Industrias Farmac?uticas Almirall, S.A. Anti-IL-23 p19 Monoclonal Antibodies Product and Services
Table 120. Industrias Farmac?uticas Almirall, S.A. Anti-IL-23 p19 Monoclonal Antibodies Production (Unit), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 121. Industrias Farmac?uticas Almirall, S.A. Recent Developments/Updates
Table 122. Industrias Farmac?uticas Almirall, S.A. Competitive Strengths & Weaknesses
Table 123. Global Key Players of Anti-IL-23 p19 Monoclonal Antibodies Upstream (Raw Materials)
Table 124. Global Anti-IL-23 p19 Monoclonal Antibodies Typical Customers
Table 125. Anti-IL-23 p19 Monoclonal Antibodies Typical Distributors
Table 1. World Anti-IL-23 p19 Monoclonal Antibodies Production Value by Region (2021, 2025 and 2032) & (USD Million)
Table 2. World Anti-IL-23 p19 Monoclonal Antibodies Production Value by Region (2021-2026) & (USD Million)
Table 3. World Anti-IL-23 p19 Monoclonal Antibodies Production Value by Region (2027-2032) & (USD Million)
Table 4. World Anti-IL-23 p19 Monoclonal Antibodies Production Value Market Share by Region (2021-2026)
Table 5. World Anti-IL-23 p19 Monoclonal Antibodies Production Value Market Share by Region (2027-2032)
Table 6. World Anti-IL-23 p19 Monoclonal Antibodies Production by Region (2021-2026) & (Unit)
Table 7. World Anti-IL-23 p19 Monoclonal Antibodies Production by Region (2027-2032) & (Unit)
Table 8. World Anti-IL-23 p19 Monoclonal Antibodies Production Market Share by Region (2021-2026)
Table 9. World Anti-IL-23 p19 Monoclonal Antibodies Production Market Share by Region (2027-2032)
Table 10. World Anti-IL-23 p19 Monoclonal Antibodies Average Price by Region (2021-2026) & (US$/Unit)
Table 11. World Anti-IL-23 p19 Monoclonal Antibodies Average Price by Region (2027-2032) & (US$/Unit)
Table 12. Anti-IL-23 p19 Monoclonal Antibodies Major Market Trends
Table 13. World Anti-IL-23 p19 Monoclonal Antibodies Consumption Growth Rate Forecast by Region (2021 & 2025 & 2032) & (Unit)
Table 14. World Anti-IL-23 p19 Monoclonal Antibodies Consumption by Region (2021-2026) & (Unit)
Table 15. World Anti-IL-23 p19 Monoclonal Antibodies Consumption Forecast by Region (2027-2032) & (Unit)
Table 16. World Anti-IL-23 p19 Monoclonal Antibodies Production Value by Manufacturer (2021-2026) & (USD Million)
Table 17. Production Value Market Share of Key Anti-IL-23 p19 Monoclonal Antibodies Producers in 2025
Table 18. World Anti-IL-23 p19 Monoclonal Antibodies Production by Manufacturer (2021-2026) & (Unit)
Table 19. Production Market Share of Key Anti-IL-23 p19 Monoclonal Antibodies Producers in 2025
Table 20. World Anti-IL-23 p19 Monoclonal Antibodies Average Price by Manufacturer (2021-2026) & (US$/Unit)
Table 21. Global Anti-IL-23 p19 Monoclonal Antibodies Company Evaluation Quadrant
Table 22. World Anti-IL-23 p19 Monoclonal Antibodies Industry Rank of Major Manufacturers, Based on Production Value in 2025
Table 23. Head Office and Anti-IL-23 p19 Monoclonal Antibodies Production Site of Key Manufacturer
Table 24. Anti-IL-23 p19 Monoclonal Antibodies Market: Company Product Type Footprint
Table 25. Anti-IL-23 p19 Monoclonal Antibodies Market: Company Product Application Footprint
Table 26. Anti-IL-23 p19 Monoclonal Antibodies Competitive Factors
Table 27. Anti-IL-23 p19 Monoclonal Antibodies New Entrant and Capacity Expansion Plans
Table 28. Anti-IL-23 p19 Monoclonal Antibodies Mergers & Acquisitions Activity
Table 29. United States VS China Anti-IL-23 p19 Monoclonal Antibodies Production Value Comparison, (2021 & 2025 & 2032) & (USD Million)
Table 30. United States VS China Anti-IL-23 p19 Monoclonal Antibodies Production Comparison, (2021 & 2025 & 2032) & (Unit)
Table 31. United States VS China Anti-IL-23 p19 Monoclonal Antibodies Consumption Comparison, (2021 & 2025 & 2032) & (Unit)
Table 32. United States Based Anti-IL-23 p19 Monoclonal Antibodies Manufacturers, Headquarters and Production Site (States, Country)
Table 33. United States Based Manufacturers Anti-IL-23 p19 Monoclonal Antibodies Production Value, (2021-2026) & (USD Million)
Table 34. United States Based Manufacturers Anti-IL-23 p19 Monoclonal Antibodies Production Value Market Share (2021-2026)
Table 35. United States Based Manufacturers Anti-IL-23 p19 Monoclonal Antibodies Production (2021-2026) & (Unit)
Table 36. United States Based Manufacturers Anti-IL-23 p19 Monoclonal Antibodies Production Market Share (2021-2026)
Table 37. China Based Anti-IL-23 p19 Monoclonal Antibodies Manufacturers, Headquarters and Production Site (Province, Country)
Table 38. China Based Manufacturers Anti-IL-23 p19 Monoclonal Antibodies Production Value, (2021-2026) & (USD Million)
Table 39. China Based Manufacturers Anti-IL-23 p19 Monoclonal Antibodies Production Value Market Share (2021-2026)
Table 40. China Based Manufacturers Anti-IL-23 p19 Monoclonal Antibodies Production, (2021-2026) & (Unit)
Table 41. China Based Manufacturers Anti-IL-23 p19 Monoclonal Antibodies Production Market Share (2021-2026)
Table 42. Rest of World Based Anti-IL-23 p19 Monoclonal Antibodies Manufacturers, Headquarters and Production Site (State, Country)
Table 43. Rest of World Based Manufacturers Anti-IL-23 p19 Monoclonal Antibodies Production Value, (2021-2026) & (USD Million)
Table 44. Rest of World Based Manufacturers Anti-IL-23 p19 Monoclonal Antibodies Production Value Market Share (2021-2026)
Table 45. Rest of World Based Manufacturers Anti-IL-23 p19 Monoclonal Antibodies Production, (2021-2026) & (Unit)
Table 46. Rest of World Based Manufacturers Anti-IL-23 p19 Monoclonal Antibodies Production Market Share (2021-2026)
Table 47. World Anti-IL-23 p19 Monoclonal Antibodies Production Value by Indication, (USD Million), 2021 & 2025 & 2032
Table 48. World Anti-IL-23 p19 Monoclonal Antibodies Production by Indication (2021-2026) & (Unit)
Table 49. World Anti-IL-23 p19 Monoclonal Antibodies Production by Indication (2027-2032) & (Unit)
Table 50. World Anti-IL-23 p19 Monoclonal Antibodies Production Value by Indication (2021-2026) & (USD Million)
Table 51. World Anti-IL-23 p19 Monoclonal Antibodies Production Value by Indication (2027-2032) & (USD Million)
Table 52. World Anti-IL-23 p19 Monoclonal Antibodies Average Price by Indication (2021-2026) & (US$/Unit)
Table 53. World Anti-IL-23 p19 Monoclonal Antibodies Average Price by Indication (2027-2032) & (US$/Unit)
Table 54. World Anti-IL-23 p19 Monoclonal Antibodies Production Value by Molecule Type, (USD Million), 2021 & 2025 & 2032
Table 55. World Anti-IL-23 p19 Monoclonal Antibodies Production by Molecule Type (2021-2026) & (Unit)
Table 56. World Anti-IL-23 p19 Monoclonal Antibodies Production by Molecule Type (2027-2032) & (Unit)
Table 57. World Anti-IL-23 p19 Monoclonal Antibodies Production Value by Molecule Type (2021-2026) & (USD Million)
Table 58. World Anti-IL-23 p19 Monoclonal Antibodies Production Value by Molecule Type (2027-2032) & (USD Million)
Table 59. World Anti-IL-23 p19 Monoclonal Antibodies Average Price by Molecule Type (2021-2026) & (US$/Unit)
Table 60. World Anti-IL-23 p19 Monoclonal Antibodies Average Price by Molecule Type (2027-2032) & (US$/Unit)
Table 61. World Anti-IL-23 p19 Monoclonal Antibodies Production Value by Route of Administration, (USD Million), 2021 & 2025 & 2032
Table 62. World Anti-IL-23 p19 Monoclonal Antibodies Production by Route of Administration (2021-2026) & (Unit)
Table 63. World Anti-IL-23 p19 Monoclonal Antibodies Production by Route of Administration (2027-2032) & (Unit)
Table 64. World Anti-IL-23 p19 Monoclonal Antibodies Production Value by Route of Administration (2021-2026) & (USD Million)
Table 65. World Anti-IL-23 p19 Monoclonal Antibodies Production Value by Route of Administration (2027-2032) & (USD Million)
Table 66. World Anti-IL-23 p19 Monoclonal Antibodies Average Price by Route of Administration (2021-2026) & (US$/Unit)
Table 67. World Anti-IL-23 p19 Monoclonal Antibodies Average Price by Route of Administration (2027-2032) & (US$/Unit)
Table 68. World Anti-IL-23 p19 Monoclonal Antibodies Production Value by Application, (USD Million), 2021 & 2025 & 2032
Table 69. World Anti-IL-23 p19 Monoclonal Antibodies Production by Application (2021-2026) & (Unit)
Table 70. World Anti-IL-23 p19 Monoclonal Antibodies Production by Application (2027-2032) & (Unit)
Table 71. World Anti-IL-23 p19 Monoclonal Antibodies Production Value by Application (2021-2026) & (USD Million)
Table 72. World Anti-IL-23 p19 Monoclonal Antibodies Production Value by Application (2027-2032) & (USD Million)
Table 73. World Anti-IL-23 p19 Monoclonal Antibodies Average Price by Application (2021-2026) & (US$/Unit)
Table 74. World Anti-IL-23 p19 Monoclonal Antibodies Average Price by Application (2027-2032) & (US$/Unit)
Table 75. AbbVie Inc. Basic Information, Manufacturing Base and Competitors
Table 76. AbbVie Inc. Major Business
Table 77. AbbVie Inc. Anti-IL-23 p19 Monoclonal Antibodies Product and Services
Table 78. AbbVie Inc. Anti-IL-23 p19 Monoclonal Antibodies Production (Unit), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 79. AbbVie Inc. Recent Developments/Updates
Table 80. AbbVie Inc. Competitive Strengths & Weaknesses
Table 81. Johnson & Johnson Basic Information, Manufacturing Base and Competitors
Table 82. Johnson & Johnson Major Business
Table 83. Johnson & Johnson Anti-IL-23 p19 Monoclonal Antibodies Product and Services
Table 84. Johnson & Johnson Anti-IL-23 p19 Monoclonal Antibodies Production (Unit), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 85. Johnson & Johnson Recent Developments/Updates
Table 86. Johnson & Johnson Competitive Strengths & Weaknesses
Table 87. Eli Lilly and Company Basic Information, Manufacturing Base and Competitors
Table 88. Eli Lilly and Company Major Business
Table 89. Eli Lilly and Company Anti-IL-23 p19 Monoclonal Antibodies Product and Services
Table 90. Eli Lilly and Company Anti-IL-23 p19 Monoclonal Antibodies Production (Unit), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 91. Eli Lilly and Company Recent Developments/Updates
Table 92. Eli Lilly and Company Competitive Strengths & Weaknesses
Table 93. Sun Pharmaceutical Industries Limited Basic Information, Manufacturing Base and Competitors
Table 94. Sun Pharmaceutical Industries Limited Major Business
Table 95. Sun Pharmaceutical Industries Limited Anti-IL-23 p19 Monoclonal Antibodies Product and Services
Table 96. Sun Pharmaceutical Industries Limited Anti-IL-23 p19 Monoclonal Antibodies Production (Unit), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 97. Sun Pharmaceutical Industries Limited Recent Developments/Updates
Table 98. Sun Pharmaceutical Industries Limited Competitive Strengths & Weaknesses
Table 99. Innovent Biologics, Inc. Basic Information, Manufacturing Base and Competitors
Table 100. Innovent Biologics, Inc. Major Business
Table 101. Innovent Biologics, Inc. Anti-IL-23 p19 Monoclonal Antibodies Product and Services
Table 102. Innovent Biologics, Inc. Anti-IL-23 p19 Monoclonal Antibodies Production (Unit), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 103. Innovent Biologics, Inc. Recent Developments/Updates
Table 104. Innovent Biologics, Inc. Competitive Strengths & Weaknesses
Table 105. Hansoh Pharmaceutical Group Company Limited Basic Information, Manufacturing Base and Competitors
Table 106. Hansoh Pharmaceutical Group Company Limited Major Business
Table 107. Hansoh Pharmaceutical Group Company Limited Anti-IL-23 p19 Monoclonal Antibodies Product and Services
Table 108. Hansoh Pharmaceutical Group Company Limited Anti-IL-23 p19 Monoclonal Antibodies Production (Unit), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 109. Hansoh Pharmaceutical Group Company Limited Recent Developments/Updates
Table 110. Hansoh Pharmaceutical Group Company Limited Competitive Strengths & Weaknesses
Table 111. SUN Pharmaceuticals Industries Europe B.V. Basic Information, Manufacturing Base and Competitors
Table 112. SUN Pharmaceuticals Industries Europe B.V. Major Business
Table 113. SUN Pharmaceuticals Industries Europe B.V. Anti-IL-23 p19 Monoclonal Antibodies Product and Services
Table 114. SUN Pharmaceuticals Industries Europe B.V. Anti-IL-23 p19 Monoclonal Antibodies Production (Unit), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 115. SUN Pharmaceuticals Industries Europe B.V. Recent Developments/Updates
Table 116. SUN Pharmaceuticals Industries Europe B.V. Competitive Strengths & Weaknesses
Table 117. Industrias Farmac?uticas Almirall, S.A. Basic Information, Manufacturing Base and Competitors
Table 118. Industrias Farmac?uticas Almirall, S.A. Major Business
Table 119. Industrias Farmac?uticas Almirall, S.A. Anti-IL-23 p19 Monoclonal Antibodies Product and Services
Table 120. Industrias Farmac?uticas Almirall, S.A. Anti-IL-23 p19 Monoclonal Antibodies Production (Unit), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 121. Industrias Farmac?uticas Almirall, S.A. Recent Developments/Updates
Table 122. Industrias Farmac?uticas Almirall, S.A. Competitive Strengths & Weaknesses
Table 123. Global Key Players of Anti-IL-23 p19 Monoclonal Antibodies Upstream (Raw Materials)
Table 124. Global Anti-IL-23 p19 Monoclonal Antibodies Typical Customers
Table 125. Anti-IL-23 p19 Monoclonal Antibodies Typical Distributors
LIST OF FIGURES
Figure 1. Anti-IL-23 p19 Monoclonal Antibodies Picture
Figure 2. World Anti-IL-23 p19 Monoclonal Antibodies Production Value: 2021 & 2025 & 2032, (USD Million)
Figure 3. World Anti-IL-23 p19 Monoclonal Antibodies Production Value and Forecast (2021-2032) & (USD Million)
Figure 4. World Anti-IL-23 p19 Monoclonal Antibodies Production (2021-2032) & (Unit)
Figure 5. World Anti-IL-23 p19 Monoclonal Antibodies Average Price (2021-2032) & (US$/Unit)
Figure 6. World Anti-IL-23 p19 Monoclonal Antibodies Production Value Market Share by Region (2021-2032)
Figure 7. World Anti-IL-23 p19 Monoclonal Antibodies Production Market Share by Region (2021-2032)
Figure 8. North America Anti-IL-23 p19 Monoclonal Antibodies Production (2021-2032) & (Unit)
Figure 9. Europe Anti-IL-23 p19 Monoclonal Antibodies Production (2021-2032) & (Unit)
Figure 10. China Anti-IL-23 p19 Monoclonal Antibodies Production (2021-2032) & (Unit)
Figure 11. Japan Anti-IL-23 p19 Monoclonal Antibodies Production (2021-2032) & (Unit)
Figure 12. Anti-IL-23 p19 Monoclonal Antibodies Market Drivers
Figure 13. Factors Affecting Demand
Figure 14. World Anti-IL-23 p19 Monoclonal Antibodies Consumption (2021-2032) & (Unit)
Figure 15. World Anti-IL-23 p19 Monoclonal Antibodies Consumption Market Share by Region (2021-2032)
Figure 16. United States Anti-IL-23 p19 Monoclonal Antibodies Consumption (2021-2032) & (Unit)
Figure 17. China Anti-IL-23 p19 Monoclonal Antibodies Consumption (2021-2032) & (Unit)
Figure 18. Europe Anti-IL-23 p19 Monoclonal Antibodies Consumption (2021-2032) & (Unit)
Figure 19. Japan Anti-IL-23 p19 Monoclonal Antibodies Consumption (2021-2032) & (Unit)
Figure 20. South Korea Anti-IL-23 p19 Monoclonal Antibodies Consumption (2021-2032) & (Unit)
Figure 21. ASEAN Anti-IL-23 p19 Monoclonal Antibodies Consumption (2021-2032) & (Unit)
Figure 22. India Anti-IL-23 p19 Monoclonal Antibodies Consumption (2021-2032) & (Unit)
Figure 23. Producer Shipments of Anti-IL-23 p19 Monoclonal Antibodies by Manufacturer Revenue ($MM) and Market Share (%): 2025
Figure 24. Global Four-firm Concentration Ratios (CR4) for Anti-IL-23 p19 Monoclonal Antibodies Markets in 2025
Figure 25. Global Four-firm Concentration Ratios (CR8) for Anti-IL-23 p19 Monoclonal Antibodies Markets in 2025
Figure 26. United States VS China: Anti-IL-23 p19 Monoclonal Antibodies Production Value Market Share Comparison (2021 & 2025 & 2032)
Figure 27. United States VS China: Anti-IL-23 p19 Monoclonal Antibodies Production Market Share Comparison (2021 & 2025 & 2032)
Figure 28. United States VS China: Anti-IL-23 p19 Monoclonal Antibodies Consumption Market Share Comparison (2021 & 2025 & 2032)
Figure 29. United States Based Manufacturers Anti-IL-23 p19 Monoclonal Antibodies Production Market Share 2025
Figure 30. China Based Manufacturers Anti-IL-23 p19 Monoclonal Antibodies Production Market Share 2025
Figure 31. Rest of World Based Manufacturers Anti-IL-23 p19 Monoclonal Antibodies Production Market Share 2025
Figure 32. World Anti-IL-23 p19 Monoclonal Antibodies Production Value by Indication, (USD Million), 2021 & 2025 & 2032
Figure 33. World Anti-IL-23 p19 Monoclonal Antibodies Production Value Market Share by Indication in 2025
Figure 34. Plaque Psoriasis
Figure 35. Psoriatic Arthritis
Figure 36. Crohn's Disease
Figure 37. Ulcerative Colitis
Figure 38. Others
Figure 39. World Anti-IL-23 p19 Monoclonal Antibodies Production Market Share by Indication (2021-2032)
Figure 40. World Anti-IL-23 p19 Monoclonal Antibodies Production Value Market Share by Indication (2021-2032)
Figure 41. World Anti-IL-23 p19 Monoclonal Antibodies Average Price by Indication (2021-2032) & (US$/Unit)
Figure 42. World Anti-IL-23 p19 Monoclonal Antibodies Production Value by Molecule Type, (USD Million), 2021 & 2025 & 2032
Figure 43. World Anti-IL-23 p19 Monoclonal Antibodies Production Value Market Share by Molecule Type in 2025
Figure 44. Humanized IgG Monoclonal Antibodies
Figure 45. Fully Human IgG Monoclonal Antibodies
Figure 46. Fc-engineered or Long-acting Antibodies
Figure 47. Others
Figure 48. World Anti-IL-23 p19 Monoclonal Antibodies Production Market Share by Molecule Type (2021-2032)
Figure 49. World Anti-IL-23 p19 Monoclonal Antibodies Production Value Market Share by Molecule Type (2021-2032)
Figure 50. World Anti-IL-23 p19 Monoclonal Antibodies Average Price by Molecule Type (2021-2032) & (US$/Unit)
Figure 51. World Anti-IL-23 p19 Monoclonal Antibodies Production Value by Route of Administration, (USD Million), 2021 & 2025 & 2032
Figure 52. World Anti-IL-23 p19 Monoclonal Antibodies Production Value Market Share by Route of Administration in 2025
Figure 53. Subcutaneous Injection
Figure 54. Intravenous Induction plus Subcutaneous Maintenance
Figure 55. Intravenous Injection
Figure 56. Others
Figure 57. World Anti-IL-23 p19 Monoclonal Antibodies Production Market Share by Route of Administration (2021-2032)
Figure 58. World Anti-IL-23 p19 Monoclonal Antibodies Production Value Market Share by Route of Administration (2021-2032)
Figure 59. World Anti-IL-23 p19 Monoclonal Antibodies Average Price by Route of Administration (2021-2032) & (US$/Unit)
Figure 60. World Anti-IL-23 p19 Monoclonal Antibodies Production Value by Application, (USD Million), 2021 & 2025 & 2032
Figure 61. World Anti-IL-23 p19 Monoclonal Antibodies Production Value Market Share by Application in 2025
Figure 62. Hospitals
Figure 63. Specialist Clinics
Figure 64. Infusion Centers
Figure 65. Specialty Pharmacies
Figure 66. Retail and DTP Pharmacies
Figure 67. Others
Figure 68. World Anti-IL-23 p19 Monoclonal Antibodies Production Market Share by Application (2021-2032)
Figure 69. World Anti-IL-23 p19 Monoclonal Antibodies Production Value Market Share by Application (2021-2032)
Figure 70. World Anti-IL-23 p19 Monoclonal Antibodies Average Price by Application (2021-2032) & (US$/Unit)
Figure 71. Anti-IL-23 p19 Monoclonal Antibodies Industry Chain
Figure 72. Anti-IL-23 p19 Monoclonal Antibodies Procurement Model
Figure 73. Anti-IL-23 p19 Monoclonal Antibodies Sales Model
Figure 74. Anti-IL-23 p19 Monoclonal Antibodies Sales Channels, Direct Sales, and Distribution
Figure 75. Methodology
Figure 76. Research Process and Data Source
Figure 1. Anti-IL-23 p19 Monoclonal Antibodies Picture
Figure 2. World Anti-IL-23 p19 Monoclonal Antibodies Production Value: 2021 & 2025 & 2032, (USD Million)
Figure 3. World Anti-IL-23 p19 Monoclonal Antibodies Production Value and Forecast (2021-2032) & (USD Million)
Figure 4. World Anti-IL-23 p19 Monoclonal Antibodies Production (2021-2032) & (Unit)
Figure 5. World Anti-IL-23 p19 Monoclonal Antibodies Average Price (2021-2032) & (US$/Unit)
Figure 6. World Anti-IL-23 p19 Monoclonal Antibodies Production Value Market Share by Region (2021-2032)
Figure 7. World Anti-IL-23 p19 Monoclonal Antibodies Production Market Share by Region (2021-2032)
Figure 8. North America Anti-IL-23 p19 Monoclonal Antibodies Production (2021-2032) & (Unit)
Figure 9. Europe Anti-IL-23 p19 Monoclonal Antibodies Production (2021-2032) & (Unit)
Figure 10. China Anti-IL-23 p19 Monoclonal Antibodies Production (2021-2032) & (Unit)
Figure 11. Japan Anti-IL-23 p19 Monoclonal Antibodies Production (2021-2032) & (Unit)
Figure 12. Anti-IL-23 p19 Monoclonal Antibodies Market Drivers
Figure 13. Factors Affecting Demand
Figure 14. World Anti-IL-23 p19 Monoclonal Antibodies Consumption (2021-2032) & (Unit)
Figure 15. World Anti-IL-23 p19 Monoclonal Antibodies Consumption Market Share by Region (2021-2032)
Figure 16. United States Anti-IL-23 p19 Monoclonal Antibodies Consumption (2021-2032) & (Unit)
Figure 17. China Anti-IL-23 p19 Monoclonal Antibodies Consumption (2021-2032) & (Unit)
Figure 18. Europe Anti-IL-23 p19 Monoclonal Antibodies Consumption (2021-2032) & (Unit)
Figure 19. Japan Anti-IL-23 p19 Monoclonal Antibodies Consumption (2021-2032) & (Unit)
Figure 20. South Korea Anti-IL-23 p19 Monoclonal Antibodies Consumption (2021-2032) & (Unit)
Figure 21. ASEAN Anti-IL-23 p19 Monoclonal Antibodies Consumption (2021-2032) & (Unit)
Figure 22. India Anti-IL-23 p19 Monoclonal Antibodies Consumption (2021-2032) & (Unit)
Figure 23. Producer Shipments of Anti-IL-23 p19 Monoclonal Antibodies by Manufacturer Revenue ($MM) and Market Share (%): 2025
Figure 24. Global Four-firm Concentration Ratios (CR4) for Anti-IL-23 p19 Monoclonal Antibodies Markets in 2025
Figure 25. Global Four-firm Concentration Ratios (CR8) for Anti-IL-23 p19 Monoclonal Antibodies Markets in 2025
Figure 26. United States VS China: Anti-IL-23 p19 Monoclonal Antibodies Production Value Market Share Comparison (2021 & 2025 & 2032)
Figure 27. United States VS China: Anti-IL-23 p19 Monoclonal Antibodies Production Market Share Comparison (2021 & 2025 & 2032)
Figure 28. United States VS China: Anti-IL-23 p19 Monoclonal Antibodies Consumption Market Share Comparison (2021 & 2025 & 2032)
Figure 29. United States Based Manufacturers Anti-IL-23 p19 Monoclonal Antibodies Production Market Share 2025
Figure 30. China Based Manufacturers Anti-IL-23 p19 Monoclonal Antibodies Production Market Share 2025
Figure 31. Rest of World Based Manufacturers Anti-IL-23 p19 Monoclonal Antibodies Production Market Share 2025
Figure 32. World Anti-IL-23 p19 Monoclonal Antibodies Production Value by Indication, (USD Million), 2021 & 2025 & 2032
Figure 33. World Anti-IL-23 p19 Monoclonal Antibodies Production Value Market Share by Indication in 2025
Figure 34. Plaque Psoriasis
Figure 35. Psoriatic Arthritis
Figure 36. Crohn's Disease
Figure 37. Ulcerative Colitis
Figure 38. Others
Figure 39. World Anti-IL-23 p19 Monoclonal Antibodies Production Market Share by Indication (2021-2032)
Figure 40. World Anti-IL-23 p19 Monoclonal Antibodies Production Value Market Share by Indication (2021-2032)
Figure 41. World Anti-IL-23 p19 Monoclonal Antibodies Average Price by Indication (2021-2032) & (US$/Unit)
Figure 42. World Anti-IL-23 p19 Monoclonal Antibodies Production Value by Molecule Type, (USD Million), 2021 & 2025 & 2032
Figure 43. World Anti-IL-23 p19 Monoclonal Antibodies Production Value Market Share by Molecule Type in 2025
Figure 44. Humanized IgG Monoclonal Antibodies
Figure 45. Fully Human IgG Monoclonal Antibodies
Figure 46. Fc-engineered or Long-acting Antibodies
Figure 47. Others
Figure 48. World Anti-IL-23 p19 Monoclonal Antibodies Production Market Share by Molecule Type (2021-2032)
Figure 49. World Anti-IL-23 p19 Monoclonal Antibodies Production Value Market Share by Molecule Type (2021-2032)
Figure 50. World Anti-IL-23 p19 Monoclonal Antibodies Average Price by Molecule Type (2021-2032) & (US$/Unit)
Figure 51. World Anti-IL-23 p19 Monoclonal Antibodies Production Value by Route of Administration, (USD Million), 2021 & 2025 & 2032
Figure 52. World Anti-IL-23 p19 Monoclonal Antibodies Production Value Market Share by Route of Administration in 2025
Figure 53. Subcutaneous Injection
Figure 54. Intravenous Induction plus Subcutaneous Maintenance
Figure 55. Intravenous Injection
Figure 56. Others
Figure 57. World Anti-IL-23 p19 Monoclonal Antibodies Production Market Share by Route of Administration (2021-2032)
Figure 58. World Anti-IL-23 p19 Monoclonal Antibodies Production Value Market Share by Route of Administration (2021-2032)
Figure 59. World Anti-IL-23 p19 Monoclonal Antibodies Average Price by Route of Administration (2021-2032) & (US$/Unit)
Figure 60. World Anti-IL-23 p19 Monoclonal Antibodies Production Value by Application, (USD Million), 2021 & 2025 & 2032
Figure 61. World Anti-IL-23 p19 Monoclonal Antibodies Production Value Market Share by Application in 2025
Figure 62. Hospitals
Figure 63. Specialist Clinics
Figure 64. Infusion Centers
Figure 65. Specialty Pharmacies
Figure 66. Retail and DTP Pharmacies
Figure 67. Others
Figure 68. World Anti-IL-23 p19 Monoclonal Antibodies Production Market Share by Application (2021-2032)
Figure 69. World Anti-IL-23 p19 Monoclonal Antibodies Production Value Market Share by Application (2021-2032)
Figure 70. World Anti-IL-23 p19 Monoclonal Antibodies Average Price by Application (2021-2032) & (US$/Unit)
Figure 71. Anti-IL-23 p19 Monoclonal Antibodies Industry Chain
Figure 72. Anti-IL-23 p19 Monoclonal Antibodies Procurement Model
Figure 73. Anti-IL-23 p19 Monoclonal Antibodies Sales Model
Figure 74. Anti-IL-23 p19 Monoclonal Antibodies Sales Channels, Direct Sales, and Distribution
Figure 75. Methodology
Figure 76. Research Process and Data Source
